Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease

Human Brain Mapping

Volumn 35, Issue 7, 2014, Pages 3132-3142

  Chiu, Ming Jang ^a,b   Chen, Ya Fang ^c   Chen, Ta Fu ^a   Yang, Shieh Yueh ^d,e   Yang, Fan Pei Gloria ^f   Tseng, Tien Wen ^a   Chieh, Jen Jie ^d   Chen, Jia Chun Rare ^a   Tzen, Kai Yuan ^b,c   Hua, Mau Sun ^a,b   Horng, Herng Er ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^e MAGQU CO LTD   (Taiwan)

^f NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Biomarker; Hippocampus; Immunomagnetic reduction; MRI volumetry; Plasma total tau; Voxel based morphometry

Indexed keywords

MAGNETIC NANOPARTICLE; TAU PROTEIN; APOLIPOPROTEIN E; NANOPARTICLE;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN FUNCTION; BRAIN REGION; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GRAY MATTER; GRAY MATTER DENSITY; HEREDITY; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; INFERIOR FRONTAL GYRUS; LANGUAGE ABILITY; MALE; MEMORY; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRECUNEUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPERIOR FRONTAL GYRUS; SUPERIOR TEMPORAL GYRUS; SUPRAMARGINAL GYRUS; TAIWAN; THREE DIMENSIONAL IMAGING; VISION; VOLUMETRY; VOXEL BASED MORPHOMETRY; BLOOD; BRAIN; COMPLICATION; DIAGNOSTIC USE; GENETICS; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; REGRESSION ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NANOPARTICLES; NEUROPSYCHOLOGICAL TESTS; REGRESSION ANALYSIS; TAU PROTEINS;

EID: 84902168439     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22390     Document Type: Article

References (48)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011): The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270-279.
2. Andersson JLR, Jenkinson M, Smith S (2007): "Non-linear optimization." FMRIB technical report TR07JA1. Available at: www.fmrib.ox.ac.uk/analysis/techrep.
3. Bennet DA, Schneider JA, Wilson RS, Bienas JL, Arnold SE (2004): Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61:378-384.
4. Bielewicz J, Kurzepa J, Czekajska-chehab E, Stelmasiak Z, Bartosik-Psujek H (2011): Does serum tau protein predict the outcome of patients with ischemic stroke? J Mol Neurosc 43:241-245.
5. Chen TF, Chen YF, Cheng TW, Hua MS, Liu HM, Chiu MJ (2009): Executive dysfunction and periventricular diffusion tensor changes in amnesic mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 30:3826-3836.
6. Chen TF, Lin CC, Chen YF, Liu HM, Hua MS, Huang YC, Chiu MJ (2009): Diffusion tensor changes in patients with amnesic mild cognitive impairment and various dementias. Psychiatry Res Neuroimaging 173:15-21.
7. Chiu MJ, Horng HE, Chieh JJ, Liao SH, Chen CH, Shih BY, Yang CC, Lee CL, Chen TF, Yang SY, Hong CY, Yang HC (2011): Multi-channel SQID-based ultra-high-sensitivity in-vitro detections for biomarkers of Alzheimer's disease via immunomagnetic reduction. IEEE Trans Appl Supercond 21:477-480.
8. Chiu MJ, Yang SY, TF Chen, Chieh JJ, Huang TZ, Yip PK, Yang HC, Cheng TW, Chen YF, Hua MS, Hong HE (2012): New assay for old markers-Plasma beta amyloid of mild cognitive impairement and Alzheimer's disease. Curr Alzheimer Res 9:1142-1148.
9. de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Lehéricy S, Dubois B, Sarazin M (2012): CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging 33:1253-1257.
10. Desikan RS, McEvoy LK, Thompson WT, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM; Alzheimer's Disease Neuroimaging Initiative (2011): Amyloid-b associated volume loss occurs only in the presence of phospho-Tau. Ann Neurol 70:657-661.
11. Fazekas F, Chawluk JB, Alavi A, Hurtig HZ, Zimmerman RA (1987): MR signal abnormalities in Alzheimer's disease and normal aging. AJR Am J Roentgenol 49:351-356.
12. Good C, Johnsrude I, Ashburner J, Henson R, Friston K, Frackowiak R (2001): A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage 14:21-36.
13. Guannalopoulos P, Herrmann FR, Bussiere T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR (2003): Tangles and neuron number but not amyloid load predict cognitive status in Alzheimer's disease. Neurology 60:1495-1500.
14. Hampel H, Bürger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, Möller HJ, Teipel SJ (2005): Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 62:770-773.
15. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008): Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4:38-48.
16. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ (2010): Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45:30-40.
17. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K (2000): Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2:199-206.
18. Hua MS, Chang BS, Lin KN, Yang JM, Lu SR, Chen SY. 2005. Wechsler memory scale, 3rd ed. Chinese Behavioral Science Corporation.
19. Ingelson M, Blomberg M, Benedikz E, Wahlund LO, Karlsson E, Vanmechelen E, Lannfelt L (1999): Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dement Geriatr Cogn Disord 10:442-445.
20. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004): Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925-931.
21. Jenkinson M, Smith SM (2001): A global optimisation method for robust affine registration of brain images. Med Image Anal 5:143-156.
22. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001): Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 71:401-403.
23. Karp A, Kareholt I, Qiu C, Bellander T, Winblad B, Fratiglioni L (2004): Relation of education and occupation-based socioeconomic status to incident Alzheimer's disease. Am J Epidemiol 159:175-183.
24. Kötitz R, Weitschies W, Trahms L, Brewer W, Semmler WJ (1999): Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles. J Magn Magn Mater 194:62-68.
25. Liliang PC, Liang CL, Lu K, Wang KW, Weng HC, Hsieh CH, Tsai YD, Chen HJ (2010): Relationship between injury severity and serum tau protein levels in traumatic brain injured rats. Resuscitation 10:1205-1208.
26. Liliang PC, Liang CL, Weng HC, Lu K, Wang KW, Chen HJ, Chuang JH (2010): Tau Proteins in Serum Predict Outcome After Severe Traumatic Brain Injury. J Surg Res 160:302-307.
27. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M (2007): Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord 23:241-245.
28. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011): The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269.
29. Meng X, D'Arcy C (2012): Education and dementia in the context of the cognitive reserve hypothesis: A systemic review with meta-analyses and qualitative analyses. PLoS One 7:e38268.
30. Mörtberg E, Zetterberg H, Nordmark J, Blennow K, Catry C, Decraemer H, Vanmechelen E, Rubertsson S (2011): Plasma tau protein in comatose patients after cardiac arrest with therapeutic hypothermia. Acta Anaesthesiol Scand 55:1132-1138.
31. Nelson PT, Braak H, Markesbery WR (2009): Neuropathology and cognitive impairment in Alzheimer's disease: a complex but coherent relationship. J Neurol Exp Neurol 68:1-14.
32. Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Sakai K, Yamada M (2011): Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease. J Neurol 258:1464-1468.
33. Patenaude B, Smith SM, Kennedy D, Jenkinson M (2011): A Bayesian model of shape and appearance for subcortical brain. NeuroImage 6:907-922.
34. Perrin RJ, Fagan AM, Holtzman DM (2009): Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 15:916-922.
35. Petersen RC (2004): Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183-194.
36. Roma'n GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC (2002): Subcortical ischaemic vascular dementia. Lancet Neurol 1:426-436.
37. Sattler C, Toro P, Schonknecht P, Schroder J (2012): Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196:90-95.
38. Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA (1995): Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 242:557-560.
39. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004): Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23:S208-S219.
40. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002): Accurate, robust and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17:479-489.
41. Sparks DL, Kryscio RJ, Sabbagh MN, Ziolkowski C, Lin Y, Sparks LM, Liebsack C, Johnson-Traver S (2012): Tau is reduced in AD plasma and validation of employed EISA methods. Am J Neurodegener Dis 1:99-106.
42. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011): Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 7:280-292.
43. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009): Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer -type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
44. van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P (2012): Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis 29:319-327.
45. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative (2010): Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75:143-151.
46. Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Yang HC, Chen KH, Shih BY, Chen TF, Chiu MJ (2011): Bio-functionalzied magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro. ACS Chem Neurosci 2:500-505.
47. Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D (1999): Quantification of axonal damage in traumatic brain injury: Affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem 72:741-750.
48. Zhang Y, Brady M, Smith S (2001): Segmentation of brain MR images through a hidden Markov random field model and the expectation maximization algorithm. IEEE Trans Med Imaging 20:45-57.